X-TOLE2 · XPF-010-301
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures EudraCT 2022-502000-73-00
Sponsor: Xenon Pharmaceuticals
Phase: III
Area: Epilepsy